IL243645B - Preparations, methods and kits for the diagnosis and treatment of diseases associated with cells expressing cd206 - Google Patents
Preparations, methods and kits for the diagnosis and treatment of diseases associated with cells expressing cd206Info
- Publication number
- IL243645B IL243645B IL243645A IL24364516A IL243645B IL 243645 B IL243645 B IL 243645B IL 243645 A IL243645 A IL 243645A IL 24364516 A IL24364516 A IL 24364516A IL 243645 B IL243645 B IL 243645B
- Authority
- IL
- Israel
- Prior art keywords
- diagnosing
- kits
- compositions
- treating
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361857232P | 2013-07-22 | 2013-07-22 | |
| US201361879649P | 2013-09-18 | 2013-09-18 | |
| PCT/US2014/047708 WO2015013341A1 (en) | 2013-07-22 | 2014-07-22 | Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL243645A0 IL243645A0 (en) | 2016-02-29 |
| IL243645B true IL243645B (en) | 2019-12-31 |
Family
ID=51352773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL243645A IL243645B (en) | 2013-07-22 | 2016-01-17 | Preparations, methods and kits for the diagnosis and treatment of diseases associated with cells expressing cd206 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150023876A1 (enExample) |
| EP (1) | EP3024493A1 (enExample) |
| JP (1) | JP6607854B2 (enExample) |
| KR (2) | KR20210095972A (enExample) |
| CN (2) | CN105764529A (enExample) |
| AU (3) | AU2014293198A1 (enExample) |
| CA (1) | CA2918782C (enExample) |
| HK (1) | HK1225623A1 (enExample) |
| IL (1) | IL243645B (enExample) |
| WO (1) | WO2015013341A1 (enExample) |
| ZA (1) | ZA201600453B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100196272A1 (en) | 2009-01-30 | 2010-08-05 | Neoprobe Corporation | Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran |
| US10806803B2 (en) | 2014-07-17 | 2020-10-20 | Ohio State Innovation Foundation | Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis |
| JP6722663B2 (ja) * | 2014-07-17 | 2020-07-15 | オハイオ ステート イノベーション ファウンデーション | マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法 |
| JP2018528235A (ja) * | 2015-09-25 | 2018-09-27 | セリーン・エルエルシー | Ｓｎ−１１７ｍ標識マンノース結合デキストランアミン |
| MX2019003897A (es) * | 2016-10-04 | 2019-11-18 | Cardinal Health 414 Llc | Composiciones y metodos para el diagnostico y el tratamiento de trastornos relacionados con macrofagos que utilizan el transportador macromolecular a base de carbohidratos. |
| MX2019004033A (es) * | 2016-10-07 | 2019-12-05 | Navidea Biopharmaceuticals Inc | Compuestos y composiciones para el tratamiento de la leishmaniasis y metodos de diagnostico y tratamiento que utilizan los mismos. |
| US11007272B1 (en) | 2016-10-07 | 2021-05-18 | Navidea Biopharmaceuticals, Inc. | Compounds and methods for diagnosis and treatment of viral infections |
| US11363709B2 (en) | 2017-02-24 | 2022-06-14 | BWXT Isotope Technology Group, Inc. | Irradiation targets for the production of radioisotopes |
| US11286172B2 (en) | 2017-02-24 | 2022-03-29 | BWXT Isotope Technology Group, Inc. | Metal-molybdate and method for making the same |
| JP2020521021A (ja) * | 2017-05-19 | 2020-07-16 | ナビディア・バイオファーマシューティカルズ，インコーポレーテッド | Ｃｄ２０６＋マクロファージ特異的分子画像化のプローブ組成物および方法、ならびにヒトにおける動脈壁マクロファージ浸潤の非侵襲的定量化 |
| EP3655107A4 (en) * | 2017-07-21 | 2021-04-28 | Navidea Biopharmaceuticals, Inc. | Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions |
| CN114025666A (zh) * | 2019-01-25 | 2022-02-08 | 纳维迪亚生物制药有限公司 | 用于评估巨噬细胞介导的病理学的组合物和方法 |
| GB201902810D0 (en) * | 2019-03-01 | 2019-04-17 | Vidya Holdings Ltd | Disposition of reagents in assay device |
| MX2021011703A (es) * | 2019-03-27 | 2022-01-06 | Navidea Biopharmaceuticals Inc | Composiciones y métodos para alterar el fenotipo de macrófagos. |
| WO2021034953A1 (en) * | 2019-08-19 | 2021-02-25 | Navidea Biopharmaceuticals, Inc. | Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells |
| CN115151264B (zh) * | 2019-09-30 | 2024-03-12 | 纳维迪亚生物制药有限公司 | 用于阻断甘露糖基化葡聚糖和其它cd206配体脱靶定位的组合物和相关方法 |
| GB201915222D0 (en) * | 2019-10-21 | 2019-12-04 | Univ Court Univ Of Glasgow | Diagnostic and prognostic biomarkers of disease remission in rheumatoid arthritis |
| JP2023533405A (ja) * | 2020-07-08 | 2023-08-03 | ナビディア、バイオファーマスーティカルズ、インコーポレイテッド | 均一に定められた分子量のマンノシル化デキストランおよびその誘導体の合成 |
| WO2022157373A1 (en) * | 2021-01-25 | 2022-07-28 | Vrije Universiteit Brussel | Compositions and kits for in vivo imaging of cardiac sarcoidosis |
| CN113899909A (zh) * | 2021-09-30 | 2022-01-07 | 上海交通大学医学院附属瑞金医院 | 可溶性cd206在制备抗中性粒细胞胞浆抗体相关性血管炎诊断试剂盒中的应用 |
| EP4472643A1 (en) | 2022-02-04 | 2024-12-11 | Navidea Biopharmaceuticals, Inc. | Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking |
| WO2023183922A2 (en) * | 2022-03-25 | 2023-09-28 | Navidea Biopharmaceuticals, Inc. | Competitive self-blocking with unlabeled manocept imaging agents |
| EP4525882A1 (en) | 2022-05-20 | 2025-03-26 | Navidea Biopharmaceuticals, Inc. | Cd206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker |
| US12404349B2 (en) | 2022-10-03 | 2025-09-02 | Navidea Biopharmaceuticals, Inc. | Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers |
| WO2024178142A1 (en) * | 2023-02-22 | 2024-08-29 | Resolute Science, Inc. | Compositions and methods for targeting tumor-associated macrophages |
| CN119592679B (zh) * | 2024-11-25 | 2025-06-24 | 中日友好医院(中日友好临床医学研究所) | 一种用于评估皮肌炎/抗合成酶综合征相关间质性肺疾病严重程度及预后的新型标记物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE277642T1 (de) * | 1999-05-14 | 2004-10-15 | Univ California | Makromolekular träger auf basis von dextran fur arzneimittel und diagnosticum abgabe |
| JP2004085929A (ja) * | 2002-08-27 | 2004-03-18 | Fuji Photo Optical Co Ltd | 光学素子 |
| US20090311182A1 (en) * | 2004-03-31 | 2009-12-17 | Dong Wang | Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases |
| US20100196272A1 (en) | 2009-01-30 | 2010-08-05 | Neoprobe Corporation | Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran |
| SG166016A1 (en) * | 2009-04-16 | 2010-11-29 | Fan Wang Yiang | Financial education planner and method of using thereof |
| US9101674B2 (en) * | 2010-03-29 | 2015-08-11 | Vib Vzw | Targeting and in vivo imaging of tumor-associated macrophages |
| US20130330274A1 (en) * | 2012-05-22 | 2013-12-12 | University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group | Compositions and methods for detecting and treating cancer |
-
2014
- 2014-07-22 HK HK16113910.2A patent/HK1225623A1/zh unknown
- 2014-07-22 CN CN201480051858.9A patent/CN105764529A/zh active Pending
- 2014-07-22 KR KR1020217023825A patent/KR20210095972A/ko not_active Ceased
- 2014-07-22 WO PCT/US2014/047708 patent/WO2015013341A1/en not_active Ceased
- 2014-07-22 AU AU2014293198A patent/AU2014293198A1/en not_active Abandoned
- 2014-07-22 EP EP14750851.9A patent/EP3024493A1/en active Pending
- 2014-07-22 CA CA2918782A patent/CA2918782C/en active Active
- 2014-07-22 JP JP2016529843A patent/JP6607854B2/ja active Active
- 2014-07-22 CN CN202111299877.1A patent/CN114377143A/zh active Pending
- 2014-07-22 US US14/338,332 patent/US20150023876A1/en not_active Abandoned
- 2014-07-22 KR KR1020167004069A patent/KR102284389B1/ko not_active Expired - Fee Related
-
2016
- 2016-01-17 IL IL243645A patent/IL243645B/en active IP Right Grant
- 2016-01-20 ZA ZA2016/00453A patent/ZA201600453B/en unknown
-
2020
- 2020-01-15 AU AU2020200293A patent/AU2020200293B2/en active Active
-
2021
- 2021-02-19 US US17/180,471 patent/US20220016272A1/en active Pending
-
2022
- 2022-07-13 AU AU2022205225A patent/AU2022205225A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020200293A1 (en) | 2020-02-06 |
| CN105764529A (zh) | 2016-07-13 |
| AU2022205225A1 (en) | 2022-08-04 |
| WO2015013341A1 (en) | 2015-01-29 |
| JP6607854B2 (ja) | 2019-11-20 |
| KR20160055791A (ko) | 2016-05-18 |
| US20220016272A1 (en) | 2022-01-20 |
| AU2020200293B2 (en) | 2022-04-21 |
| KR102284389B1 (ko) | 2021-08-03 |
| EP3024493A1 (en) | 2016-06-01 |
| CA2918782A1 (en) | 2015-01-29 |
| ZA201600453B (en) | 2019-09-25 |
| IL243645A0 (en) | 2016-02-29 |
| JP2016527252A (ja) | 2016-09-08 |
| CN114377143A (zh) | 2022-04-22 |
| AU2014293198A1 (en) | 2016-02-04 |
| HK1225623A1 (zh) | 2017-09-15 |
| US20150023876A1 (en) | 2015-01-22 |
| KR20210095972A (ko) | 2021-08-03 |
| CA2918782C (en) | 2024-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201600453B (en) | Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders | |
| IL267997A (en) | Preparations, formulations and methods for treating eye diseases | |
| EP2986140A4 (en) | COMPOSITIONS, PROCESSES AND KIT FOR TREATMENT OF PETS | |
| SI2986304T1 (sl) | Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe | |
| SG11201508027PA (en) | Methods and compositions for mobilizing stem cells | |
| EP3024497A4 (en) | Methods and compositions for treating brain diseases | |
| EP3046470A4 (en) | Diagnosing and treating movement disorders | |
| IL241191B (en) | Local compositions and kits that include them for the treatment of local disorders | |
| HK1220980A1 (zh) | 用於治疗庞贝氏症的方法和组合物 | |
| EP3071215A4 (en) | Compositions and methods for treating pulmonary hypertension | |
| ZA201605027B (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| EP2979687A4 (en) | ARTIFICIAL NAIL COMPOSITION, ARTIFICIAL NAIL, METHOD OF FORMING ARTIFICIAL NAIL, AND NAIL DECORATION KIT | |
| EP2966445A4 (en) | TINTANT FOR DYING OF TISSUE, MANUFACTURING PROCESS FOR TINTING AGENT FOR TISSUE AND TISSUE COLORING TINTANT FOR TISSUE COLORING | |
| EP3077049A4 (en) | Compositions and methods for treating vitiligo | |
| FI3511422T3 (fi) | Menetelmiä ja koostumuksia endometriooosin diagnosointia, ennustamista ja hoitoa varten | |
| EP3008167A4 (en) | Compositions and methods for treating metabolic disorders | |
| WO2014168973A3 (en) | Methods and compositions for rejuvenating skeletal muscle stem cells | |
| EP3079680A4 (en) | Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders | |
| EP2989123A4 (en) | METHODS AND COMPOSITIONS FOR TREATING COAGULATION DISORDERS | |
| AU2014306716B2 (en) | Compositions and methods for treating celiac sprue disease | |
| IL246202A0 (en) | Methods for t-cell epitope sorting, preparation of t-cell preparations and treatment of diseases | |
| IL244532A0 (en) | A mechanism for producing a diagnostic kit, and a diagnostic kit produced therefrom | |
| PL2988764T3 (pl) | Kompozycje przeciwłupieżowe i sposoby ich zastosowania | |
| PL2956491T3 (pl) | Duroplasty, sposoby wytwarzania, zastosowania i kompozycje składników | |
| EP3065550A4 (en) | Methods and compositions for treating sepsis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |